Steve Boatwright led a team at Gallagher & Kennedy in representing IsoRay, Inc. in its closing of a $8,250,000 registered direct offering with several institutional investors of 11,000,000 shares of its common stock at a price of $0.75 per share. IsoRay, Inc. is a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancer.
G&K Represents IsoRay, Inc. in $8,250,000 Registered Direct Offering
